Oculis to present Phase 2 Privosegtor biomarker data
Share
Oculis (NASDAQ:OCS) will present new Phase 2 ACUITY biomarker analyses of its investigational Privosegtor treatment on October 22, 2026, in Toronto.
Oculis (NASDAQ:OCS) will present new Phase 2 ACUITY biomarker analyses of its investigational Privosegtor treatment on October 22, 2026, in Toronto.
Oculis (NASDAQ:OCS) signed an agreement to acquire worldwide development and commercial rights to Privosegtor (ACT-01) from Accure Therapeutics, along with rights to an early-stage neurology candidate known as ACT-02.
Oculis Holding (NASDAQ:OCS) announced it has randomized the first patient in its PREDICT-1 clinical trial, marking the launch of the first genotype-based registrational study aimed at treating dry eye disease.
Oculis Holding (NASDAQ:OCS), a global biopharmaceutical company focused on ophthalmic breakthroughs, announced today the completion of the final patient visits in its DIAMOND Phase 3 clinical program.
Oculis (NASDAQ:OCS) will present its investigational dry eye treatment, Licaminlimab, at the Eyecelerator @ AAO 2026 conference on October 8.
Oculis (NASDAQ:OCS) announced on March 31, 2026, that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation to Privosegtor for the treatment of optic neuritis.
